BR112021020424A2 - Compostos e métodos para tratamento de distúrbios inflamatórios - Google Patents
Compostos e métodos para tratamento de distúrbios inflamatóriosInfo
- Publication number
- BR112021020424A2 BR112021020424A2 BR112021020424A BR112021020424A BR112021020424A2 BR 112021020424 A2 BR112021020424 A2 BR 112021020424A2 BR 112021020424 A BR112021020424 A BR 112021020424A BR 112021020424 A BR112021020424 A BR 112021020424A BR 112021020424 A2 BR112021020424 A2 BR 112021020424A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- methods
- inflammatory disorders
- treating inflammatory
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833140P | 2019-04-12 | 2019-04-12 | |
| PCT/US2020/027981 WO2020210823A1 (en) | 2019-04-12 | 2020-04-13 | Compounds and methods for treating inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021020424A2 true BR112021020424A2 (pt) | 2021-12-21 |
Family
ID=72751451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021020424A BR112021020424A2 (pt) | 2019-04-12 | 2020-04-13 | Compostos e métodos para tratamento de distúrbios inflamatórios |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12398093B2 (https=) |
| EP (2) | EP3952851B1 (https=) |
| JP (1) | JP7596296B2 (https=) |
| KR (1) | KR20220008264A (https=) |
| CN (2) | CN113784709B (https=) |
| AU (1) | AU2020271915B2 (https=) |
| BR (1) | BR112021020424A2 (https=) |
| CA (1) | CA3136153A1 (https=) |
| WO (1) | WO2020210823A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL309842A (en) * | 2021-07-26 | 2024-02-01 | Univ Louisiana State | Compounds and methods for treating situations where the response depends on 5-HT2 |
| SE2151519A1 (en) | 2021-12-10 | 2023-06-11 | Amidea Sweden Ab | 2-(2,5-dimethoxyphenyl)ethanamine and uses thereof |
| WO2024010765A1 (en) * | 2022-07-05 | 2024-01-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions for treating 5-ht2 conditions and methods of using the same |
| WO2024191924A2 (en) * | 2023-03-10 | 2024-09-19 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007016190A2 (en) * | 2005-07-28 | 2007-02-08 | Duke University | Antiparkinsonian action of phenylisopropylamines |
| US9642819B2 (en) * | 2008-07-10 | 2017-05-09 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical | Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation |
| EP2884962B1 (en) * | 2012-08-17 | 2019-05-01 | Smartek International LLC | Preparation of desiccated liposomes for use in compressible delivery systems |
| US20200078335A1 (en) * | 2017-05-01 | 2020-03-12 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods to reduce pathogenesis |
| GB201715919D0 (en) | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
-
2020
- 2020-04-13 EP EP20788460.2A patent/EP3952851B1/en active Active
- 2020-04-13 US US17/603,091 patent/US12398093B2/en active Active
- 2020-04-13 CN CN202080030668.4A patent/CN113784709B/zh active Active
- 2020-04-13 BR BR112021020424A patent/BR112021020424A2/pt not_active Application Discontinuation
- 2020-04-13 EP EP25219576.3A patent/EP4685135A3/en active Pending
- 2020-04-13 JP JP2021559994A patent/JP7596296B2/ja active Active
- 2020-04-13 CN CN202410485765.2A patent/CN118384143A/zh active Pending
- 2020-04-13 WO PCT/US2020/027981 patent/WO2020210823A1/en not_active Ceased
- 2020-04-13 AU AU2020271915A patent/AU2020271915B2/en active Active
- 2020-04-13 KR KR1020217036157A patent/KR20220008264A/ko not_active Ceased
- 2020-04-13 CA CA3136153A patent/CA3136153A1/en active Pending
-
2025
- 2025-07-16 US US19/271,350 patent/US20260070872A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113784709B (zh) | 2024-05-10 |
| US20220119340A1 (en) | 2022-04-21 |
| EP4685135A3 (en) | 2026-04-15 |
| EP4685135A2 (en) | 2026-01-28 |
| KR20220008264A (ko) | 2022-01-20 |
| JP2022527401A (ja) | 2022-06-01 |
| WO2020210823A1 (en) | 2020-10-15 |
| JP7596296B2 (ja) | 2024-12-09 |
| EP3952851B1 (en) | 2025-12-03 |
| EP3952851A4 (en) | 2023-01-11 |
| CA3136153A1 (en) | 2020-10-15 |
| AU2020271915A1 (en) | 2021-11-04 |
| US12398093B2 (en) | 2025-08-26 |
| CN113784709A (zh) | 2021-12-10 |
| AU2020271915B2 (en) | 2025-10-09 |
| EP3952851A1 (en) | 2022-02-16 |
| US20260070872A1 (en) | 2026-03-12 |
| CN118384143A (zh) | 2024-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021020424A2 (pt) | Compostos e métodos para tratamento de distúrbios inflamatórios | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| CY1125065T1 (el) | Αναστολεις mcl-1 | |
| BR112022003335A2 (pt) | Conjugados de il-2 e métodos de uso para tratar doenças autoimunes | |
| BR112017026189A2 (pt) | tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4 | |
| BR112018012914A2 (pt) | composto, método para tratar, prevenir ou melhorar um ou mais sintomas de câncer, método para tratar, prevenir ou melhorar um ou mais sintomas de uma doença inflamatória e composição farmacêutica | |
| BR112021023024A2 (pt) | Anticorpo contra claudina 18a2 e uso do mesmo | |
| BR112022009631A2 (pt) | Combinações de inibidores de dgk e antagonistas do ponto de checagem | |
| BR112015023207A2 (pt) | uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase | |
| BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| CO2018000410A2 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| BR112016018980A2 (pt) | método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica | |
| BR112021025645A2 (pt) | Degradação de proteína alvo de parp14 para uso em terapia | |
| BR112018016689A2 (pt) | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m1 | |
| CL2019001330A1 (es) | Inhibidores de la tirosina quinasa de bruton. | |
| EP4520395A3 (en) | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof | |
| ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
| BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
| MX2021010869A (es) | Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso. | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
| BR112019002458A2 (pt) | composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos | |
| PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
| BR112019020414A2 (pt) | composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina | |
| MX374654B (es) | Compuestos útiles para inhibir ror-gamma-t. | |
| MX2021013602A (es) | Inhibidores de jak. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |